Boya Bio-Pharmaceutical shareholders approve governance framework revisions

CR Boya Bio-Pharmaceutical Group (SZSE:300294) announced the successful approval of all proposed resolutions at its second extraordinary general meeting of shareholders for 2025, held on November 13, 2025. A total of 175 shareholders, representing 221,016,105 shares or 43.8308% of the company's total voting shares, participated in the meeting. Resolutions included revisions to the company's articles of association, rules of procedure for general meetings, and rules of procedure for board meetings, all passed with over 98% of votes in favor.

Key approvals also encompassed updates to the company’s governance policies, specifically the "Management System for Raised Funds," "Management System for External Investments," "Management System for Network Voting at Shareholders' Meetings," "Independent Director Work System," "Director Allowance System," "Related Party Transaction Decision-Making System," and "Cumulative Voting System." These proposals were each approved with high majority votes, ranging from 98.7448% to 99.6494% of the total voting shares present.

For instance, the revision to the "Director Allowance System" garnered 220,241,245 votes in favor, representing 99.6494% of participating shares, while the "Management System for Raised Funds" received 218,249,605 votes (98.7483% in favor). Small and medium-sized investors' votes were counted separately, with the majority also supporting these changes.